Latest Information Update: 13 Feb 1995
$50 / €47 *
At a glance
- Originator Gliatech (CEASED)
- Developer Gliatech (CEASED); Janssen L.P.
- Class Neuroprotectants; Nootropics
- Mechanism of Action Amyloid beta-protein precursor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 13 Feb 1995 Discontinued-Preclinical for Alzheimer's disease in USA (Unknown route)